RecruitingNCT07049913

TBE Zone 2 PMS in Japan

GORE® TAG® Thoracic Branch Endoprosthesis Zone 2 Post-Market Surveillance in Japan


Sponsor

W.L.Gore & Associates

Enrollment

200 participants

Start Date

Dec 15, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this surveillance is to confirm the TBE device's safety and efficacy in patients treated with proximal landing in Zone 2 in the post-marketing period.


Eligibility

Inclusion Criteria5

  • Those who are suitable for use of TBE according to the Japan package insert.
  • \[Reference: Purpose of Use or Effects of TBE at the time of launch\] The GORE TAG Thoracic Branch Endoprosthesis is intended for use in patients with the following diseases with descending thoracic aortic lesions who fulfill anatomical requirements for treatment of such diseases while preserving blood flow to the left subclavian artery.
  • Thoracic aortic aneurysm,
  • Traumatic transection, and
  • Complicated Stanford type B aortic dissection (including dissecting aortic aneurysm) who have not responded to medical therapy.

Exclusion Criteria1

  • N/A

Interventions

DEVICEGore® TAG® Thoracic Aortic Branch Stent Graft System

Patients who attempted implant of TBE in Zone 2 during the enrollment period of this surveillance.


Locations(1)

The University of Osaka Hospital

Osaka, Suita, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07049913


Related Trials